120 related articles for article (PubMed ID: 32543134)
1. [Antitumor Activity of TRAIL-Mu3 Protein
Yang T; Zhu AJ; Wang JS; Jin Z
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):304-311. PubMed ID: 32543134
[TBL] [Abstract][Full Text] [Related]
2. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
3. 5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.
Xie ZH; Quan MF; Liu F; Cao JG; Zhang JS
BMC Cancer; 2011 Jul; 11():322. PubMed ID: 21801359
[TBL] [Abstract][Full Text] [Related]
4. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
5. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
[TBL] [Abstract][Full Text] [Related]
6. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
7. Effects of ebv-miR-BART7 on tumorigenicity, metastasis, and TRAIL sensitivity of non-small cell lung cancer.
Wang L; Liu LF; Zhou L; Liao F; Wang J
J Cell Biochem; 2019 Jun; 120(6):10057-10068. PubMed ID: 30569505
[TBL] [Abstract][Full Text] [Related]
8. Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.
Kim YH; Shin EA; Jung JH; Park JE; Koo J; Koo JI; Shim BS; Kim SH
Eur J Pharmacol; 2019 Mar; 847():91-96. PubMed ID: 30689998
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
10. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo.
Qiao X; Wang X; Shang Y; Li Y; Chen SZ
Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.
Danish L; Imig D; Allgöwer F; Scheurich P; Pollak N
PLoS One; 2018; 13(6):e0198203. PubMed ID: 29927992
[TBL] [Abstract][Full Text] [Related]
12. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
13. Construction and validation of a novel tumor necrosis factor-related apoptosis-inducing ligand mutant MuR5S4-TR.
Zhao Y; He J; Liu X; Yi C; Sun L; Zhu H
Asia Pac J Clin Oncol; 2024 Apr; 20(2):210-219. PubMed ID: 36658682
[TBL] [Abstract][Full Text] [Related]
14. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
15. Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.
Ouyang W; Yang C; Zhang S; Liu Y; Yang B; Zhang J; Zhou F; Zhou Y; Xie C
Int J Oncol; 2013 Feb; 42(2):699-711. PubMed ID: 23258590
[TBL] [Abstract][Full Text] [Related]
16. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
17. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
[TBL] [Abstract][Full Text] [Related]
18. N-Acetyl-Glucosamine Sensitizes Non-Small Cell Lung Cancer Cells to TRAIL-Induced Apoptosis by Activating Death Receptor 5.
Liang Y; Xu W; Liu S; Chi J; Zhang J; Sui A; Wang L; Liang Z; Li D; Chen Y; Niu H
Cell Physiol Biochem; 2018; 45(5):2054-2070. PubMed ID: 29533936
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
